SEC Form 4 · accession 0001690959-26-000004
Sionna Therapeutics, Inc. · SION
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua Resnick
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 5:37 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002036042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $36.73 | Jun 17, 2026 | A | 17,340 | A | — | Jun 16, 2036 | Common Stock | 17,340 | 17,340 | D |
Explanation of responses
- F1Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
- F2This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.